Patents by Inventor Harold W. Holloway
Harold W. Holloway has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10941187Abstract: The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.Type: GrantFiled: August 27, 2014Date of Patent: March 9, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Nigel H. Greig, Josephine M. Egan, Maire Doyle, Harold W. Holloway, Tracy Perry
-
Patent number: 10220028Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.Type: GrantFiled: March 13, 2017Date of Patent: March 5, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl
-
Publication number: 20170182022Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.Type: ApplicationFiled: March 13, 2017Publication date: June 29, 2017Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl
-
Patent number: 9623020Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.Type: GrantFiled: June 22, 2015Date of Patent: April 18, 2017Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl
-
Publication number: 20150359784Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.Type: ApplicationFiled: June 22, 2015Publication date: December 17, 2015Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl
-
Patent number: 9084783Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.Type: GrantFiled: December 15, 2014Date of Patent: July 21, 2015Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Nigel H. Grieg, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl
-
Publication number: 20150164877Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.Type: ApplicationFiled: December 15, 2014Publication date: June 18, 2015Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Nigel H. Grieg, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl
-
Publication number: 20150072930Abstract: The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.Type: ApplicationFiled: August 27, 2014Publication date: March 12, 2015Inventors: Nigel H. Greig, Josephine M. Egan, Maire Doyle, Harold W. Holloway, Tracy Perry
-
Patent number: 8927725Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.Type: GrantFiled: December 2, 2011Date of Patent: January 6, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl
-
Patent number: 8853160Abstract: The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.Type: GrantFiled: August 24, 2012Date of Patent: October 7, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Nigel H. Greig, Josephine M. Egan, Maire Doyle, Harold W. Holloway, Tracy Perry
-
Patent number: 8691864Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.Type: GrantFiled: July 26, 2012Date of Patent: April 8, 2014Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
-
Publication number: 20130143922Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.Type: ApplicationFiled: December 2, 2011Publication date: June 6, 2013Inventors: Nigel H. Greig, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl
-
Publication number: 20120295946Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.Type: ApplicationFiled: July 26, 2012Publication date: November 22, 2012Inventors: Nigel H. Greig, Karen T.Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
-
Patent number: 8258172Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.Type: GrantFiled: July 22, 2010Date of Patent: September 4, 2012Assignees: Raptor Pharmaceutical Corp, National Institutes of Health (NIH)Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
-
Publication number: 20110021594Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.Type: ApplicationFiled: July 22, 2010Publication date: January 27, 2011Inventors: Nigel H. Greig, Karen T.Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
-
Patent number: 7786162Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.Type: GrantFiled: January 21, 2009Date of Patent: August 31, 2010Assignees: Raptor Pharmaceutical Corp., National Institutes of Health (NIH)Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
-
Publication number: 20090131501Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.Type: ApplicationFiled: January 21, 2009Publication date: May 21, 2009Applicants: TorreyPines Therapeutics, National Institutes of Health (NIH)Inventors: Nigel H. Greig, Karen T.Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
-
Patent number: 7153882Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.Type: GrantFiled: November 2, 2001Date of Patent: December 26, 2006Assignees: The United States of America as represented by the Department of Health and Human Services, The National Institutes of Health and Axonyx, Inc.Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Timothy T. Sencrant, Tada Utsuki, Donald Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
-
Publication number: 20040138282Abstract: The present invention provides compounds and methods of administering compounds to a subject taht can reduce &bgr;APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce &bgr;APP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease &bgr;APP production.Type: ApplicationFiled: February 6, 2004Publication date: July 15, 2004Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Timothy T. Sencrant, Tada Utsuki, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
-
Patent number: 5409948Abstract: An improved method of cholinomimetic therapy for cognitive impairments associated with aging and Alzheimer's disease comprising treating a patient with an effective amount of phenserine or a pharmaceutically acceptable salt and derivatives.Type: GrantFiled: November 23, 1992Date of Patent: April 25, 1995Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Nigel H. Greig, Arnold Brossi, Timothy T. Soncrant, Harold W. Holloway, Stanley I. Rapoport, Setsu Iijima, Edward L. Spangler, Donald K. Ingram, Xue F. Pei